Researchers demonstrated that pancreatic β cells from type 2 diabetes donors can partially regain glucose responsiveness when cultured outside the diabetic environment. This recovery, driven by specific gene expression changes, identifies JAK inhibitors as potential therapeutic candidates to restore β-cell function.